raloxifene

the use of raloxifene in osteoporosis treatment

雷诺昔芬在骨质疏松症治疗中的应用

effect of raloxifene on human tissues except bone tissue

雷洛昔芬对非骨组织的影响

preparation of raloxifene hydrochloride capsules and establishment of its quality control standard

盐酸雷洛昔芬胶囊的制备及其质量标准研究

raloxifene is indicated for the treatment and prevention of osteoporosis in postmenopausal women.

雷洛昔芬是用来预防和治疗绝经后妇女的骨质疏松症的。

despite this risk, tamoxifen and another drug in this class, raloxifene, remain an extensively used and popular treatment.

虽然存在这些副作用，三苯氧胺和另一种同类药物-雷洛西芬已经被广泛用于乳腺癌的治疗。

a double blind, randomized, placebo-controlled study for raloxifene hydrochloride in prevention and treatment of menopausal osteoporosis

盐酸雷洛昔芬防治绝经后骨质疏松症随机双盲对照研究

roughly half were given daily raloxifene pills and the others, dummy pills. neither they nor their doctors knew who was taking what.

大约有一半的人服用瑞克斯芬，而剩下的人服常规药物。医生和这些人均不知她们吃的是哪种药。

prevention of bone loss by selective estrogen receptor modulators: raloxifene in the ovariectomized rat

选择性雌激素受体调节剂雷洛昔芬阻止去卵巢大鼠骨丢失的机制

raloxifene, a selective estrogen receptor modulator, is approved for the prevention and treatment of postmenopausal osteoporosis.

雷洛昔芬，选择性雌激素受体调节剂，已被批准用于预防和治疗绝经后骨质疏松症。

c. raloxifene (evista) is a selective estrogen receptor modulator. it is available for prevention and treatment of osteoporosis.

雷洛昔芬（Evista）是一种选择性雌激素受体调节剂，可以用来防治骨质疏松症。

interestingly, hyperplastic polyps occurred only in the raloxifene and placebo treatment groups.

有趣的是，增生性息肉仅见于雷洛昔芬和安慰剂治疗组。

Objective To synthesize raloxifene hydrochloride, which is a selective estrogen receptor modulator.

目的合成选择性雌激素受体调节剂盐酸雷洛昔芬.

conclusion: alendronate is more reasonable and economical than raloxifene in treating postmenopausal osteoporosis.

结论：应用阿仑磷酸钠治疗绝经后妇女骨质疏松症较他莫昔芬更为合理、经济。

alendronate may offer better improvements in bone mineral density and bone turnover than raloxifene

阿仑瞵酸钠改善骨密度和骨转换标记物效果优于雷洛昔芬

effects of raloxifene on prevention and treatment of bone loss in ovariectomized rats

雷洛昔芬对去卵巢大鼠骨丢失的防治作用

determination of related substances in raloxifene hydrochloride raw medicine by hplc

高效液相色谱法测定盐酸雷洛昔芬原料药有关物质

incidence of urinary incontinence in postmenopausal women treated with raloxifene or estrogen

雷洛昔芬或雌激素治疗对绝经后妇女尿失禁的影响

a relatively higher incidence of polyps occurred in the raloxifene group (4. 7%).

雷洛昔芬治疗组的息肉发生率相对较高（4.7%）。

the multiple outcomes of raloxifene evaluation study was the pivotal treatment trial for raloxifene.

多结局的雷洛昔芬评价研究的关键是审判，雷洛昔芬治疗。

improved synthesis of raloxifene hydrochloride

盐酸雷洛昔芬的合成改进

Raloxifene also mimics estrogen.

Raloxifene也是雌激素仿制物.

raloxifene may lower stroke risk in some postmenopausal women

雷洛昔芬可能降低了某些绝经后女性的卒中危险

synthesis of raloxifene hydrochloride as selective estrogen receptor modulator

选择性雌激素受体调节剂盐酸雷洛昔芬的合成

Despite, tamoxifen and another drug, raloxifene, remain an extensively used and popular treatment.

虽然存在这些副作用, 三苯氧胺和另一种同类药物-雷洛西芬已经被广泛用于乳腺癌的治疗.

However, researchers showed that raloxifene in combination with systemic oestrogen results in an increase in hyperplasia, she said.

然而她说，研究人员指出，雷洛昔芬的全身雌激素效应会导致异常增生增加。

effects of raloxifene on the proliferation and differentiation of bone marrow stromal cells from the osteoporosis rats

雷诺昔芬对骨质疏松大鼠骨髓基质细胞的影响

effects of raloxifene on the ere transcription activity and its relationship with estrogen receptor subtypes in vascular endothelial cells

雷洛昔芬对血管内皮细胞ERE转录活性的影响及与雌激素受体亚型的关系